Law09/25/2026@LawDesk
Supreme Court Restores Mail Access to Mifepristone in Louisiana Case
Supreme Court of the United StatesSupreme Court of the United States, 1, 1st Street Northeast, Ward 6, Washington, District of Columbia, 20543, United States
Starts 05/14/2026CONFIRMED 84% CONFIDENCE134 days agoThe order in Nos. 25A1207 and 25A1208 is dated "[May 14, 2026]" and says "The applications for stay ... are granted".^[1]
The Supreme Court stayed the Fifth Circuit's order in Louisiana v. FDA, so mifepristone can again be prescribed by telehealth and sent by mail while the case goes on; Justices Thomas and Alito dissented.
0.77
Law09/25/2026@LawDesk
Fifth Circuit Reinstates In-Person Dispensing for Mifepristone
United States Court of Appeals for the Fifth CircuitUnited States Court of Appeals Fifth Circuit, 600, Camp Street, Central Business District, French Quarter, New Orleans, Orleans Parish, Louisiana, 70130, United States
Starts 05/01/2026CONFIRMED 82% CONFIDENCE147 days agoThe opinion in No. 26-30203 is stamped "FILED May 1, 2026" and orders that "the motion to stay the 2023 REMS under 5 U.S.C. § 705 pending appeal is GRANTED".^[1]
A Fifth Circuit panel granted Louisiana a stay of the FDA's 2023 mifepristone rules, ending telehealth prescribing and mail or pharmacy dispensing of the abortion pill nationwide until the Supreme Court stepped in.
0.73
Law09/25/2026@LawDesk
Fifth Circuit Hears Louisiana's Appeal Against Mail-Order Mifepristone
United States Court of Appeals for the Fifth CircuitUnited States Court of Appeals Fifth Circuit, 600, Camp Street, Central Business District, French Quarter, New Orleans, Orleans Parish, Louisiana, 70130, United States
Starts 09/09/2026CONFIRMED 83% CONFIDENCE16 days agoThe court's recording of 26-30203 State of Louisiana v. FDA gives "Hearing Date: Wednesday, September 9, 2026 Courtroom: En Banc Courtroom".^[1]
A Fifth Circuit panel of Judges Richman, Higginson and Douglas heard Louisiana's bid to end telehealth prescribing of mifepristone and pressed the state hard on whether it has standing to sue.
0.71
Health09/25/2026@HealthDesk
FDA Approves Evita Solutions' Generic Mifepristone
Evita SolutionsMahan Court, Federal Research Center, White Oak, Montgomery County, Maryland, 20993, United States
Starts 09/30/2025 2:20PMCONFIRMED 83% CONFIDENCE360 days agoThe ANDA 216616 approval letter says "the ANDA is approved, effective on the date of this letter" and is digitally signed "Date: 9/30/2025 10:20:02AM".^[1]
The FDA approved Evita Solutions' 200 mg mifepristone tablets as the second generic of the abortion pill, less than two weeks after HHS promised a safety review of the drug.
0.66
Law09/24/2026@LawDesk
Federal Circuit Upholds Lululemon Win Against Nike Fitness-Watch Patent
Howard T. Markey National Courts Building, 717, Madison Place Northwest, Ward 2, Washington, District of Columbia, 20005, United StatesLululemon
Starts 08/05/2026 1:10PMCONFIRMED 86% CONFIDENCE51 days agoThe nonprecedential opinion in No. 2024-2134 reads "Decided: August 5, 2026"; the docket shows it entered at 09:10 AM that day.^[1]
The Federal Circuit affirmed a Patent Trial and Appeal Board ruling, won by Lululemon, that every challenged claim of Nike's patent on a heart-rate and fitness watch console is unpatentable.
0.62
Law09/24/2026@LawDesk
Federal Circuit Upholds Lululemon Win Against Nike Workout-Sharing Patent
Howard T. Markey National Courts Building, 717, Madison Place Northwest, Ward 2, Washington, District of Columbia, 20005, United StatesLululemon
Starts 05/13/2026 1:40PMCONFIRMED 86% CONFIDENCE135 days agoThe nonprecedential Rule 36 judgment in No. 2024-2074 is dated "May 13, 2026" and stamped "Filed: 05/13/2026"; the docket shows it entered at 09:40 AM that day.^[1]
The Federal Circuit affirmed without opinion a Patent Trial and Appeal Board ruling, won by Lululemon, that the challenged claims of Nike's patent on sharing recorded workouts to social networking sites are unpatentable.
0.61
Law09/25/2026@LawDesk
Third Circuit Lists Arm's Appeal Against Qualcomm for October 20
James A. Byrne Courthouse, 601, Market Street, Old City, Center City, Philadelphia, Philadelphia County, Pennsylvania, 19106, United StatesQualcomm
Starts 10/20/2026SCHEDULED 80% CONFIDENCEin 25 daysThe clerk's letter says the case 'has been tentatively listed on the merits for Tuesday, October 20, 2026, in PHILADELPHIA, PA' and may move 'to another day within the week of October 19, 2026'.^[1]
The US Court of Appeals for the Third Circuit has listed Arm's appeal of the Delaware judgment for Qualcomm and Nuvia on the merits in Philadelphia, with oral argument at the panel's discretion.
0.61
Law09/24/2026@LawDesk
Supreme Court Refuses Pirani's Last Appeal in the Slack Direct-Listing Case
Supreme Court of the United States, 1, 1st Street Northeast, Ward 6, Washington, District of Columbia, 20543, United StatesSalesforce
Starts 10/06/2025CONFIRMED 91% CONFIDENCE354 days agoThe Supreme Court's^[1][3] order list for 'MONDAY, OCTOBER 6, 2025' lists 25-44 Pirani v. Slack Technologies, Inc. under 'CERTIORARI DENIED'.
The justices denied a Slack investor's petition, leaving in place the Ninth Circuit's order to throw out his securities suit over Slack's 2019 direct listing on the NYSE.
0.60
Health09/25/2026@HealthDesk
FDA Decision Due on Roche's Giredestrant for Early Breast Cancer
RocheMahan Court, FDA White Oak Campus, White Oak, Montgomery County, Maryland, 20993, United States
Starts 11/30/2026SCHEDULED 78% CONFIDENCEin 66 daysRoche's^[1] release says "The FDA is expected to make a decision on the approval by 30 November 2026", the PDUFA goal date set under Priority Review.
The FDA is due to decide by 30 November 2026 whether to approve Roche's giredestrant, an oral SERD that cut the risk of recurrence or death by 30% versus standard hormone therapy in early ER-positive breast cancer.
0.58
Law09/25/2026@LawDesk
Fifth Circuit Strikes Down Nasdaq's Board Diversity Rule 9-8
United States Court of Appeals Fifth Circuit, 600, Camp Street, Central Business District, French Quarter, New Orleans, Orleans Parish, Louisiana, 70130, United StatesNasdaq
Starts 12/11/2024CONFIRMED 83% CONFIDENCE1.8 years agoThe en banc opinion in No. 21-60626 is stamped "FILED December 11, 2024" and "Date Filed: 12/11/2024".^[1]
The full US Court of Appeals for the Fifth Circuit voted 9-8 to vacate the SEC's approval of Nasdaq's rule requiring listed companies to have a woman and a minority or LGBTQ+ director on the board or explain why not.
0.58
Law09/24/2026@LawDesk
Judge Lets Investors' Securities Suit Against Lululemon Go Ahead
40, Centre Street, Civic Center, Lower Manhattan, Manhattan, New York County, New York, 10007, United StatesLululemon
Starts 03/31/2026CONFIRMED 91% CONFIDENCE178 days agoDocket entry 58, dated Mar 31, 2026: "ORDER granting in part and denying in part 53 Motion to Dismiss" by Judge Andrew L. Carter, Jr.^[1]
A Manhattan federal judge partly denied Lululemon's motion to dismiss a shareholder class action over its 2023-24 statements, finding plausible claims of misleading statements and scienter, citing alleged insider trading.
0.58
Law09/25/2026@LawDesk
Federal Circuit Hears ParkerVision's Appeal in Qualcomm Patent Case
Howard T. Markey National Courts Building, 717, Madison Place Northwest, Ward 2, Washington, District of Columbia, 20005, United StatesQualcomm
Starts 06/01/2026 2:00PMCONFIRMED 89% CONFIDENCE116 days agoThe Federal Circuit's notice says 'This case has been scheduled for oral argument on June 1, 2026 at 10:00 a.m.', and the court posted the argument's audio on 1 June 2026.^[1]
A Federal Circuit panel of Judges Prost, Chen and Stark heard ParkerVision's appeal of the claim construction that ended its receiver-patent claims against Qualcomm.
0.57

The slip opinion in No. 23-235 is headed "Argued March 26, 2024—Decided June 13, 2024".^[1]

Start: Jun 13, 202490% CONFIDENCEfrom the source

Supreme Court Rejects Challenge to Mifepristone in FDA v. Alliance

A unanimous Supreme Court threw out anti-abortion doctors' challenge to the FDA's rules for the abortion pill mifepristone, holding they had no standing to sue, so mail and telehealth access stayed in place.

The Supreme Court unanimously reversed the Fifth Circuit on 13 June 2024, holding that the Alliance for Hippocratic Medicine and the anti-abortion doctors with it lacked Article III standing to challenge the FDA's mifepristone rules^[1]
Justice Brett Kavanaugh wrote for the Court and Justice Clarence Thomas added a concurrence; the case was argued on 26 March 2024^[1]
The suit had begun with Judge Matthew Kacsmaryk's April 2023 order suspending the drug's 2000 approval, which the Fifth Circuit narrowed to the 2016 and later changes, including mail dispensing^[2]
The ruling left mifepristone available by telehealth and mail under the FDA's 2023 rules, but decided nothing about the merits^[2][3]
Because the Court ruled only on standing, states such as Missouri, Kansas, Idaho and later Louisiana pressed their own suits against the same rules^[3]

@LawDesk

References 584% CONFIDENCE

The first entry is always the pin's source. Overall confidence is a weighted average of how firmly each reference supports the start and end times used above; a reference counts half as much for every 180 days older than the newest.

[1]90%
supremecourt.gov/opinions/23pdf/23-235_n7ip.pdf
supremecourt.gov· Posted Sep 25, 2026· Starts Jun 13, 2024 ✓· 38% of score
The slip opinion in No. 23-235 is headed "Argued March 26, 2024—Decided June 13, 2024".
[2]80%
FDA v. Alliance for Hippocratic Medicine (Wikipedia)
en.wikipedia.org· Added Sep 25, 2026· 38% of score
Case history: Judge Kacsmaryk's 7 April 2023 order suspending mifepristone's approval, the Fifth Circuit's partial stay, and the unanimous 13 June 2024 ruling that the Alliance lacked standing, restoring the drug's availability under current FDA rules.^[1]
[3]80%
Louisiana v. FDA: Access to Mifepristone Back at the Supreme Court (KFF)
kff.org· Published May 6, 2026· 22% of score
Says the 2024 ruling held the doctors and groups lacked standing to challenge FDA's approval of mifepristone but did not reach the merits, which is why state-led suits followed.^[1]
[4]80%
Access to mifepristone remains unchanged as Supreme Court rejects abortion pill challenge (PBS NewsHour)
youtube.com· Published Jun 13, 2024· 2% of score
PBS NewsHour on the day: in a unanimous decision the Court ruled anti-abortion doctors had no legal basis to challenge access to mifepristone.^[1]
[5]75%
Supreme Court rejects challenge to abortion pill mifepristone (CNN)
youtube.com· Published Jun 13, 2024· 2% of score
CNN report that the ruling continues to allow the pills to be mailed to patients without an in-person doctor's visit.^[1]

Suggest a correction

Something missing or wrong? Say it in your own words: a link that backs this pin up, a different start or end date and why, or a fact it lacks or gets wrong. The AI checks it against this pin's sources, searches for better ones, and adds any page that backs you up. The pin's own sources still count most.

Comments

Thread

Respond to this Pin

1Supreme Court Rejects Challenge to Mifepristone in FDA v. Alliance

Law09/25/2026@LawDesk
Supreme Court Restores Mail Access to Mifepristone in Louisiana Case
Supreme Court of the United StatesSupreme Court of the United States, 1, 1st Street Northeast, Ward 6, Washington, District of Columbia, 20543, United States
Starts 05/14/2026CONFIRMED 84% CONFIDENCE134 days agoThe order in Nos. 25A1207 and 25A1208 is dated "[May 14, 2026]" and says "The applications for stay ... are granted".^[1]
The Supreme Court stayed the Fifth Circuit's order in Louisiana v. FDA, so mifepristone can again be prescribed by telehealth and sent by mail while the case goes on; Justices Thomas and Alito dissented.
0.77
Law09/25/2026@LawDesk
Fifth Circuit Reinstates In-Person Dispensing for Mifepristone
United States Court of Appeals for the Fifth CircuitUnited States Court of Appeals Fifth Circuit, 600, Camp Street, Central Business District, French Quarter, New Orleans, Orleans Parish, Louisiana, 70130, United States
Starts 05/01/2026CONFIRMED 82% CONFIDENCE147 days agoThe opinion in No. 26-30203 is stamped "FILED May 1, 2026" and orders that "the motion to stay the 2023 REMS under 5 U.S.C. § 705 pending appeal is GRANTED".^[1]
A Fifth Circuit panel granted Louisiana a stay of the FDA's 2023 mifepristone rules, ending telehealth prescribing and mail or pharmacy dispensing of the abortion pill nationwide until the Supreme Court stepped in.
0.73
Law09/25/2026@LawDesk
Fifth Circuit Hears Louisiana's Appeal Against Mail-Order Mifepristone
United States Court of Appeals for the Fifth CircuitUnited States Court of Appeals Fifth Circuit, 600, Camp Street, Central Business District, French Quarter, New Orleans, Orleans Parish, Louisiana, 70130, United States
Starts 09/09/2026CONFIRMED 83% CONFIDENCE16 days agoThe court's recording of 26-30203 State of Louisiana v. FDA gives "Hearing Date: Wednesday, September 9, 2026 Courtroom: En Banc Courtroom".^[1]
A Fifth Circuit panel of Judges Richman, Higginson and Douglas heard Louisiana's bid to end telehealth prescribing of mifepristone and pressed the state hard on whether it has standing to sue.
0.71
Health09/25/2026@HealthDesk
FDA Approves Evita Solutions' Generic Mifepristone
Evita SolutionsMahan Court, Federal Research Center, White Oak, Montgomery County, Maryland, 20993, United States
Starts 09/30/2025 2:20PMCONFIRMED 83% CONFIDENCE360 days agoThe ANDA 216616 approval letter says "the ANDA is approved, effective on the date of this letter" and is digitally signed "Date: 9/30/2025 10:20:02AM".^[1]
The FDA approved Evita Solutions' 200 mg mifepristone tablets as the second generic of the abortion pill, less than two weeks after HHS promised a safety review of the drug.
0.66
Law09/24/2026@LawDesk
Federal Circuit Upholds Lululemon Win Against Nike Fitness-Watch Patent
Howard T. Markey National Courts Building, 717, Madison Place Northwest, Ward 2, Washington, District of Columbia, 20005, United StatesLululemon
Starts 08/05/2026 1:10PMCONFIRMED 86% CONFIDENCE51 days agoThe nonprecedential opinion in No. 2024-2134 reads "Decided: August 5, 2026"; the docket shows it entered at 09:10 AM that day.^[1]
The Federal Circuit affirmed a Patent Trial and Appeal Board ruling, won by Lululemon, that every challenged claim of Nike's patent on a heart-rate and fitness watch console is unpatentable.
0.62
Law09/24/2026@LawDesk
Federal Circuit Upholds Lululemon Win Against Nike Workout-Sharing Patent
Howard T. Markey National Courts Building, 717, Madison Place Northwest, Ward 2, Washington, District of Columbia, 20005, United StatesLululemon
Starts 05/13/2026 1:40PMCONFIRMED 86% CONFIDENCE135 days agoThe nonprecedential Rule 36 judgment in No. 2024-2074 is dated "May 13, 2026" and stamped "Filed: 05/13/2026"; the docket shows it entered at 09:40 AM that day.^[1]
The Federal Circuit affirmed without opinion a Patent Trial and Appeal Board ruling, won by Lululemon, that the challenged claims of Nike's patent on sharing recorded workouts to social networking sites are unpatentable.
0.61
Law09/25/2026@LawDesk
Third Circuit Lists Arm's Appeal Against Qualcomm for October 20
James A. Byrne Courthouse, 601, Market Street, Old City, Center City, Philadelphia, Philadelphia County, Pennsylvania, 19106, United StatesQualcomm
Starts 10/20/2026SCHEDULED 80% CONFIDENCEin 25 daysThe clerk's letter says the case 'has been tentatively listed on the merits for Tuesday, October 20, 2026, in PHILADELPHIA, PA' and may move 'to another day within the week of October 19, 2026'.^[1]
The US Court of Appeals for the Third Circuit has listed Arm's appeal of the Delaware judgment for Qualcomm and Nuvia on the merits in Philadelphia, with oral argument at the panel's discretion.
0.61
Law09/24/2026@LawDesk
Supreme Court Refuses Pirani's Last Appeal in the Slack Direct-Listing Case
Supreme Court of the United States, 1, 1st Street Northeast, Ward 6, Washington, District of Columbia, 20543, United StatesSalesforce
Starts 10/06/2025CONFIRMED 91% CONFIDENCE354 days agoThe Supreme Court's^[1][3] order list for 'MONDAY, OCTOBER 6, 2025' lists 25-44 Pirani v. Slack Technologies, Inc. under 'CERTIORARI DENIED'.
The justices denied a Slack investor's petition, leaving in place the Ninth Circuit's order to throw out his securities suit over Slack's 2019 direct listing on the NYSE.
0.60
Health09/25/2026@HealthDesk
FDA Decision Due on Roche's Giredestrant for Early Breast Cancer
RocheMahan Court, FDA White Oak Campus, White Oak, Montgomery County, Maryland, 20993, United States
Starts 11/30/2026SCHEDULED 78% CONFIDENCEin 66 daysRoche's^[1] release says "The FDA is expected to make a decision on the approval by 30 November 2026", the PDUFA goal date set under Priority Review.
The FDA is due to decide by 30 November 2026 whether to approve Roche's giredestrant, an oral SERD that cut the risk of recurrence or death by 30% versus standard hormone therapy in early ER-positive breast cancer.
0.58
Law09/25/2026@LawDesk
Fifth Circuit Strikes Down Nasdaq's Board Diversity Rule 9-8
United States Court of Appeals Fifth Circuit, 600, Camp Street, Central Business District, French Quarter, New Orleans, Orleans Parish, Louisiana, 70130, United StatesNasdaq
Starts 12/11/2024CONFIRMED 83% CONFIDENCE1.8 years agoThe en banc opinion in No. 21-60626 is stamped "FILED December 11, 2024" and "Date Filed: 12/11/2024".^[1]
The full US Court of Appeals for the Fifth Circuit voted 9-8 to vacate the SEC's approval of Nasdaq's rule requiring listed companies to have a woman and a minority or LGBTQ+ director on the board or explain why not.
0.58
Law09/24/2026@LawDesk
Judge Lets Investors' Securities Suit Against Lululemon Go Ahead
40, Centre Street, Civic Center, Lower Manhattan, Manhattan, New York County, New York, 10007, United StatesLululemon
Starts 03/31/2026CONFIRMED 91% CONFIDENCE178 days agoDocket entry 58, dated Mar 31, 2026: "ORDER granting in part and denying in part 53 Motion to Dismiss" by Judge Andrew L. Carter, Jr.^[1]
A Manhattan federal judge partly denied Lululemon's motion to dismiss a shareholder class action over its 2023-24 statements, finding plausible claims of misleading statements and scienter, citing alleged insider trading.
0.58
Law09/25/2026@LawDesk
Federal Circuit Hears ParkerVision's Appeal in Qualcomm Patent Case
Howard T. Markey National Courts Building, 717, Madison Place Northwest, Ward 2, Washington, District of Columbia, 20005, United StatesQualcomm
Starts 06/01/2026 2:00PMCONFIRMED 89% CONFIDENCE116 days agoThe Federal Circuit's notice says 'This case has been scheduled for oral argument on June 1, 2026 at 10:00 a.m.', and the court posted the argument's audio on 1 June 2026.^[1]
A Federal Circuit panel of Judges Prost, Chen and Stark heard ParkerVision's appeal of the claim construction that ended its receiver-patent claims against Qualcomm.
0.57

More like this

References 584% CONFIDENCE

Suggest a correction

Comments

Thread

More like this